Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A112C8 | ISIN: FR0010120402 | Ticker-Symbol: 941
Stuttgart
02.05.24
16:04 Uhr
0,342 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
THERACLION Chart 1 Jahr
5-Tage-Chart
THERACLION 5-Tage-Chart
RealtimeGeldBriefZeit
0,2960,39602.05.

Aktuelle News zur THERACLION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.03.Theraclion Announces 2023 Financial Results and Continues Its Roadmap205Continuation of the strategy focused on access to the US and Chinese markets for SONOVEIN®, and its improvement through R&D; Rapid start-up of the pivotal study in the United States: two-thirds...
► Artikel lesen
29.01.Theraclion Pursues Its Strategy and Announces Its 2023 Revenue437Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive focused ultrasound therapy (HIFU),...
► Artikel lesen
14.12.23Theraclion Delivers Its 2023 Strategic Objectives357Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, is now taking stock of its achievements...
► Artikel lesen
24.10.23Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated With SONOVEIN as Part of the FDA-approved Pivotal Study409Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announced today...
► Artikel lesen
11.10.23Theraclion Announces Its Half-year Financial Results for 2023 and Provides an Update on the Execution of Its Strategy494Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a robotic platform for non-invasive ultrasound therapy, presents its half-year financial...
► Artikel lesen
31.07.23Theraclion Executes Strategy in First Half of 2023388Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, presents its review of the first...
► Artikel lesen
22.06.23Theraclion Announces the Success of Its Capital Increase484Conclusion of a major partnership with long-standing shareholder Furui. Financial resources strengthened, ensuring the company's financial visibility over the next 2 years. Theraclion...
► Artikel lesen
25.05.23Theraclion Announces Strategic Partnership, Capital Raise and CEO Appointment572Signing of a strategic partnership with Furui, a leading Chinese healthcare player and Theraclion's long-term partner Launch of a global financing of up to 15M€ Appointment of Martin...
► Artikel lesen
8 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1